152 related articles for article (PubMed ID: 2098651)
1. [Advances in insulin treatment. Evaluation of isophane or lente insulin, mixed with rapid insulin and injected twice-a-day].
Cucinotta D; Lunetta M
Minerva Endocrinol; 1990; 15(2):111-6. PubMed ID: 2098651
[TBL] [Abstract][Full Text] [Related]
2. Premixed insulin at ratio 3/7 and regular + isophane insulins at mixing ratios from 2/8 to 4/6 achieve the same metabolic control.
Cucinotta D; Mannino D; Lasco A; Di Cesare E; Musolino C; Alessi R
Diabete Metab; 1991; 17(1):49-54. PubMed ID: 1868960
[TBL] [Abstract][Full Text] [Related]
3. The effect of insulin mixtures in type I diabetics: influence of the intermediate acting insulin on the action of short acting insulin.
Goicolea I; Quiroga A; Vazquez JA
Diabete Metab; 1987; 13(4):467-70. PubMed ID: 3315768
[TBL] [Abstract][Full Text] [Related]
4. A randomized, controlled trial comparing twice-a-day insulin glargine mixed with rapid-acting insulin analogs versus standard neutral protamine Hagedorn (NPH) therapy in newly diagnosed type 1 diabetes.
Hassan K; Rodriguez LM; Johnson SE; Tadlock S; Heptulla RA
Pediatrics; 2008 Mar; 121(3):e466-72. PubMed ID: 18299307
[TBL] [Abstract][Full Text] [Related]
5. Miscibility of human semisynthetic regular and lente insulin and human biosynthetic regular and NPH insulin.
Olsson PO; Hans A; Henning VS
Diabetes Care; 1987; 10(4):473-7. PubMed ID: 3304898
[TBL] [Abstract][Full Text] [Related]
6. Intermediate and long-acting insulins: a review of NPH insulin, insulin glargine and insulin detemir.
Peterson GE
Curr Med Res Opin; 2006 Dec; 22(12):2613-9. PubMed ID: 17166343
[TBL] [Abstract][Full Text] [Related]
7. Injection of acidic or neutral insulin and pain: a single-center, prospective, controlled, noninterventional study in pediatric patients with type 1 diabetes mellitus.
Karges B; Muche R; Riegger I; Moritz M; Heinze E; Debatin KM; Wabitsch M; Karges W
Clin Ther; 2006 Dec; 28(12):2094-101. PubMed ID: 17296465
[TBL] [Abstract][Full Text] [Related]
8. Intermediate-acting insulin preparations: NPH and lente.
Deckert T
Diabetes Care; 1980; 3(5):623-6. PubMed ID: 7192205
[TBL] [Abstract][Full Text] [Related]
9. [Therapeutic qualities of a lente preparation of swine insulins manufactured by Pharmachem].
Andreev D; Bozadzhieva E; Pampulov L; Penchev I; Uzunova B
Vutr Boles; 1977; 16(6):59-66. PubMed ID: 341532
[TBL] [Abstract][Full Text] [Related]
10. The contribution of intermediate-acting insulin preparations to daytime insulin treatment.
Robert JJ; Chevenne D; Debray M
Diabet Med; 1989 Aug; 6(6):531-6. PubMed ID: 2527136
[TBL] [Abstract][Full Text] [Related]
11. Double-blind crossover trial of isophane (NPH)- and lente-based insulin regimens.
Tunbridge FK; Newens A; Home PD; Davis SN; Murphy M; Burrin JM; Alberti KG; Jensen I
Diabetes Care; 1989 Feb; 12(2):115-9. PubMed ID: 2649324
[TBL] [Abstract][Full Text] [Related]
12. [Insulin combinations: improving the treatment of juvenile diabetes].
Gúrpide Arraya N; Durá Travé T; Moya Benavent M
Rev Enferm; 1997; 20(227-8):17-20. PubMed ID: 9282075
[TBL] [Abstract][Full Text] [Related]
13. Insulin therapy in cats with diabetes mellitus.
Moise NS; Reimers TJ
J Am Vet Med Assoc; 1983 Jan; 182(2):158-64. PubMed ID: 6298164
[TBL] [Abstract][Full Text] [Related]
14. The effect of mixing regular- and intermediate-acting insulins on their absorption and biological activity.
Schulz B; Menzel R; Besch W
Exp Clin Endocrinol; 1988 Mar; 91(1):27-34. PubMed ID: 3286272
[TBL] [Abstract][Full Text] [Related]
15. Pharmacology of a 40 IU/ml porcine lente insulin preparation in diabetic cats: findings during the first week and after 5 or 9 weeks of therapy.
Martin GJ; Rand JS
J Feline Med Surg; 2001 Mar; 3(1):23-30. PubMed ID: 11716627
[TBL] [Abstract][Full Text] [Related]
16. [Ultratard HM, a new human insulin. Advantages as compared to current preparations?].
Saner B; Fankhauser S
Schweiz Med Wochenschr; 1986 Jan; 116(4):116-9. PubMed ID: 3513303
[TBL] [Abstract][Full Text] [Related]
17. Treatment of newly diagnosed diabetic cats with glargine insulin improves glycaemic control and results in higher probability of remission than protamine zinc and lente insulins.
Marshall RD; Rand JS; Morton JM
J Feline Med Surg; 2009 Aug; 11(8):683-91. PubMed ID: 19539509
[TBL] [Abstract][Full Text] [Related]
18. Behaviour of insulin antibodies in diabetics treated with different insulins.
Mincu I; Cheţa D; Ionescu-Tîrgovişte C; Mirodon Z; Sîntu E
Med Interne; 1980; 18(4):347-52. PubMed ID: 7006044
[TBL] [Abstract][Full Text] [Related]
19. Comparison of injection techniques for soluble and protamine zinc insulins in diabetes mellitus.
Harrower AD; Duncan LJ; Clarke BF
Practitioner; 1975 Feb; 214(1280):228-31. PubMed ID: 1144249
[TBL] [Abstract][Full Text] [Related]
20. [Treatment with monocomponent semi-lente insulin in diabetes of difficult compensation].
Barbero L; Gamba S; Zanno C; Regis G; Bruni B
Minerva Med; 1978 Apr; 69(21):1437-42. PubMed ID: 683547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
